Skip to main content
Log in

Treatment of Pulmonary Hypertension in Children with Chronic Lung Disease with Newer Oral Therapies

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Chronic lung disease (CLD) is often complicated by chronic pulmonary vascular changes and pulmonary hypertension (PH) in young children. Current therapies for severe PH in such patients, including oxygen, inhaled nitric oxide, and parenteral prostacyclin, are often suboptimal, cumbersome, and expensive. Recently, oral endothelin receptor blockers and phosphodiesterase-5 inhibitors have been used successfully to control and reverse pulmonary vascular disease in idiopathic PH, but the use and efficacy of these agents in pediatric CLD have not been previously reported. We report a series of six children with CLD and severe PH treated with bosentan (six of six) and sildenafil (four of six). Vascular reactivity was assessed by cardiac catheterization prior to and after 6 months of therapy. Serial echocardiography was also used to assess response. Patients have been treated for 2.1–2.9 years (mean, 2.53 years). Response to therapy has included improvement in oxygenation, symptoms, echocardiographic parameters, and hemodynamics by cardiac catheterization. Transiently elevated liver enzymes were noted associated with viral respiratory infections in two subjects; no other adverse effects were noted. Three patients with large cardiac right-to-left shunts prior to therapy had subsequent shunt reversal, two of whom underwent shunt closure later. Oral therapy with bosentan alone or in combination with sildenafil improves PH in patients with CLD over a period of 3–4 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abman SH (2007) Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 91:283–290

    Article  PubMed  CAS  Google Scholar 

  2. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360:895–900

    Article  PubMed  CAS  Google Scholar 

  3. Grigg A, Buchanan M, Whitford H (2005) Late-onset pulmonary arterial hypertension in association with graft-versus-host disease after allogeneic stem-cell transplantation. Am J Hematol 80:38–42

    Article  PubMed  Google Scholar 

  4. Grover TR, Parker TA, Balasubramaniam V, Markham NE, Abman SH (2005) Pulmonary hypertension impairs alveolarization and reduces lung growth in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 288:L648–L654

    Article  PubMed  CAS  Google Scholar 

  5. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111(24):3274–3280 (Epub 13 June 2005)

    Article  PubMed  CAS  Google Scholar 

  6. Madden BP, Allenby M, Loke TK, Sheth A (2006) A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vasc Pharmacol 44:372–376

    Article  CAS  Google Scholar 

  7. Mourani PM, Ivy DD, Rosenberg AA, Fagan TE, Abman SH (2008) Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr 152(2):291–293

    Article  PubMed  Google Scholar 

  8. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ (2005) Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46(4):697–704

    Article  PubMed  CAS  Google Scholar 

  9. Ross RD, Bollinger RO, Pinsky WW (1992) Grading the severity of congestive heart failure in infants. Pediatr Cardiol 13:72–75

    Article  PubMed  CAS  Google Scholar 

  10. Roy R, Couriel JM (2006) Secondary pulmonary hypertension. Paediatr Respir Rev 7:36–44

    Article  PubMed  Google Scholar 

  11. Rubin LJ, Galie N (2004) Pulmonary arterial hypertension. A look to the future. J Am Coll Cardiol 43:S89–S90

    Article  Google Scholar 

  12. Stenmark KR, Abman SH (2005) Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 67:623–661

    Article  PubMed  CAS  Google Scholar 

  13. Weissmann N, Gerigk B, Kocer O, Nollen M, Hackemack S, Ghofrani HA, Schermuly RT, Butrous G, Schulz A, Roth M, Seeger W, Grimminger F (2007) Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide. Respir Med 101:2125–2132

    Article  PubMed  Google Scholar 

  14. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS (2005) Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 171:1292–1297

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Usha Krishnan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krishnan, U., Krishnan, S. & Gewitz, M. Treatment of Pulmonary Hypertension in Children with Chronic Lung Disease with Newer Oral Therapies. Pediatr Cardiol 29, 1082–1086 (2008). https://doi.org/10.1007/s00246-008-9260-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-008-9260-x

Keywords

Navigation